← Back to Search

Topical Agent

Study in Subjects With Moderate Atopic Dermatitis

Phase 2
Waitlist Available
Research Sponsored by Ralexar Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 57

Summary

This trial tests a special gel called ALX-101 on adults and adolescents with moderate atopic dermatitis. The gel is applied to the skin twice a day for several weeks to see if it helps improve their skin condition and is safe.

Eligible Conditions
  • Atopic Dermatitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 57
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 57 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Eczema Area Severity Index (EASI)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ALX-101 Gel 5%Experimental Treatment1 Intervention
ALX-101 Gel 5% applied topically twice daily for 56 days
Group II: ALX-101 Gel VehiclePlacebo Group1 Intervention
ALX-101 Gel Vehicle applied topically twice daily for 56 days

Find a Location

Who is running the clinical trial?

Ralexar Therapeutics, Inc.Lead Sponsor
1 Previous Clinical Trials
209 Total Patients Enrolled
~18 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top